OncoCyte Retained Earnings from 2010 to 2024

OCX Stock

USD 2.44 0.09 3.56%

OncoCyte Corp Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that OncoCyte Corp retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2014-12-31

Previous Quarter

-303.5 M

Current Value

-317 M

Quarterly Volatility

96.9 M

Yuan Drop

Covid

Check OncoCyte Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OncoCyte Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 49.4 K or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 12.09, Dividend Yield of 0.0015 or PTB Ratio of 0.71. OncoCyte financial statements analysis is a perfect complement when working with OncoCyte Corp Valuation or Volatility modules.

Check out the analysis of OncoCyte Corp Correlation against competitors.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

Latest OncoCyte Corp's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of OncoCyte Corp over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. OncoCyte Corp's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OncoCyte Corp's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (289.88 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

OncoCyte Retained Earnings Regression Statistics

	Arithmetic Mean	(98,240,880)
	Coefficient Of Variation	(106.40)
	Mean Deviation	86,157,440
	Median	(54,677,000)
	Standard Deviation	104,527,877
	Sample Variance	10926.1T
	Range	279.5M
	R-Value	(0.92)
	Mean Square Error	1901.5T
	R-Squared	0.84
	Slope	(21,401,409)
	Total Sum of Squares	152965.1T

OncoCyte Retained Earnings History

	2024	-275.4 M
	2023	-289.9 M
	2022	-260.7 M
	2021	-187.8 M
	2020	-123.7 M
	2019	-93.7 M
	2018	-71.3 M

Other Fundumenentals of OncoCyte Corp

Retained Earnings Total Equity

OncoCyte Corp Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Current Deferred Revenue	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments	Net Receivables
Total Assets		0.95	-0.8	-0.75	0.98	-0.55	0.98	0.88	-0.04	0.93	0.8	0.82	-0.71	0.72	0.65	0.55	0.68	0.92	0.73	0.86	-0.78	0.82
Total Stockholder Equity	0.95		-0.82	-0.68	0.91	-0.59	0.88	0.91	-0.1	0.84	0.74	0.79	-0.5	0.79	0.72	0.59	0.75	0.98	0.76	0.76	-0.63	0.69
Net Debt	-0.8	-0.82		0.54	-0.85	0.62	-0.74	-0.96	0.44	-0.74	-0.6	-0.56	0.4	-0.6	-0.41	-0.62	-0.6	-0.75	-0.85	-0.58	0.61	-0.68
Retained Earnings	-0.75	-0.68	0.54		-0.76	0.76	-0.76	-0.58	0.26	-0.88	-0.99	-0.97	0.58	-0.73	-0.7	-0.73	-0.75	-0.67	-0.3	-0.96	0.89	-0.64
Accounts Payable	0.98	0.91	-0.85	-0.76		-0.56	0.98	0.9	-0.14	0.93	0.8	0.8	-0.73	0.68	0.57	0.57	0.64	0.86	0.73	0.86	-0.83	0.85
Short Term Investments	-0.55	-0.59	0.62	0.76	-0.56		-0.5	-0.56	0.47	-0.61	-0.77	-0.72	0.14	-0.75	-0.77	-0.93	-0.82	-0.57	-0.29	-0.64	0.52	-0.37
Total Liab	0.98	0.88	-0.74	-0.76	0.98	-0.5		0.82	0.0	0.94	0.79	0.8	-0.82	0.64	0.57	0.5	0.61	0.84	0.67	0.87	-0.84	0.87
Total Current Assets	0.88	0.91	-0.96	-0.58	0.9	-0.56	0.82		-0.24	0.8	0.65	0.64	-0.48	0.65	0.47	0.57	0.63	0.88	0.9	0.65	-0.65	0.76
Short Term Debt	-0.04	-0.1	0.44	0.26	-0.14	0.47	0.0	-0.24		-0.1	-0.24	-0.16	-0.18	-0.2	-0.15	-0.53	-0.25	0.03	-0.03	-0.14	0.17	-0.05
Intangible Assets	0.93	0.84	-0.74	-0.88	0.93	-0.61	0.94	0.8	-0.1		0.91	0.9	-0.8	0.64	0.57	0.6	0.64	0.83	0.6	0.92	-0.93	0.79
Common Stock	0.8	0.74	-0.6	-0.99	0.8	-0.77	0.79	0.65	-0.24	0.91		0.99	-0.6	0.75	0.72	0.74	0.77	0.74	0.37	0.96	-0.89	0.66
Property Plant Equipment	0.82	0.79	-0.56	-0.97	0.8	-0.72	0.8	0.64	-0.16	0.9	0.99		-0.59	0.77	0.77	0.7	0.78	0.79	0.36	0.95	-0.85	0.62
Net Tangible Assets	-0.71	-0.5	0.4	0.58	-0.73	0.14	-0.82	-0.48	-0.18	-0.8	-0.6	-0.59		-0.18	-0.18	-0.17	-0.18	-0.51	-0.34	-0.67	0.82	-0.7
Long Term Debt	0.72	0.79	-0.6	-0.73	0.68	-0.75	0.64	0.65	-0.2	0.64	0.75	0.77	-0.18		0.84	0.72	0.98	0.76	0.55	0.75	-0.51	0.48
Short Long Term Debt	0.65	0.72	-0.41	-0.7	0.57	-0.77	0.57	0.47	-0.15	0.57	0.72	0.77	-0.18	0.84		0.77	0.83	0.71	0.22	0.68	-0.37	0.37
Current Deferred Revenue	0.55	0.59	-0.62	-0.73	0.57	-0.93	0.5	0.57	-0.53	0.6	0.74	0.7	-0.17	0.72	0.77		0.78	0.57	0.29	0.61	-0.5	0.36
Long Term Debt Total	0.68	0.75	-0.6	-0.75	0.64	-0.82	0.61	0.63	-0.25	0.64	0.77	0.78	-0.18	0.98	0.83	0.78		0.74	0.5	0.73	-0.53	0.44
Net Invested Capital	0.92	0.98	-0.75	-0.67	0.86	-0.57	0.84	0.88	0.03	0.83	0.74	0.79	-0.51	0.76	0.71	0.57	0.74		0.74	0.73	-0.62	0.66
Net Working Capital	0.73	0.76	-0.85	-0.3	0.73	-0.29	0.67	0.9	-0.03	0.6	0.37	0.36	-0.34	0.55	0.22	0.29	0.5	0.74		0.42	-0.45	0.64
Capital Stock	0.86	0.76	-0.58	-0.96	0.86	-0.64	0.87	0.65	-0.14	0.92	0.96	0.95	-0.67	0.75	0.68	0.61	0.73	0.73	0.42		-0.91	0.75
Long Term Investments	-0.78	-0.63	0.61	0.89	-0.83	0.52	-0.84	-0.65	0.17	-0.93	-0.89	-0.85	0.82	-0.51	-0.37	-0.5	-0.53	-0.62	-0.45	-0.91		-0.75
Net Receivables	0.82	0.69	-0.68	-0.64	0.85	-0.37	0.87	0.76	-0.05	0.79	0.66	0.62	-0.7	0.48	0.37	0.36	0.44	0.66	0.64	0.75	-0.75

Click cells to compare fundamentals

About OncoCyte Corp Financial Statements

OncoCyte Corp investors use historical fundamental indicators, such as OncoCyte Corp's Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in OncoCyte Corp. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-289.9 M	-275.4 M
Retained Earnings Total Equity	-234.6 M	-222.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC